[Special Stock] Anigen Shows Strong Rise Expected to Leap Globally in Peptides Based on Over 10 Years of Joint Development of Innovative New Drugs

[Asia Economy Reporter Yoo Hyun-seok] Anigen is showing strong performance. The news that it has filed patents through joint research and development with Gwangju Institute of Science and Technology to claim domestic and international priority rights for three innovative new drug treatments appears to be influencing its stock price. The patented treatments include a nucleolin-targeting novel peptide anticancer carrier, a peptide antibiotic for multidrug-resistant super bacteria, and a GPCR-targeting peptide metabolic disease treatment for diabetes and obesity.

As of 10:12 AM on the 15th, Anigen was trading at 10,900 KRW, up 3.81% (400 KRW) from the previous trading day.

Anigen has conducted joint research on global innovative new drugs with Gwangju Institute of Science and Technology over the past decade. Recently, it has been filing patents to secure intellectual property rights for some research results. Anigen is also proceeding with technology transfer of these patents from Gwangju Institute of Science and Technology to obtain exclusive ownership and commercialization rights.

Kim Jae-il, CEO of Anigen, stated, "We plan to continuously focus all efforts on the production of peptide active pharmaceutical ingredients (APIs), contract manufacturing for new drug clinical trials, and innovative new drug development. We aim to become a global peptide-specialized company that mass-produces peptide APIs and clinical trial peptides and develops innovative peptide new drugs."

The nucleolin-targeting novel peptide anticancer carrier patent is a platform technology applicable to all currently used anticancer drugs. It improves the water solubility of poorly soluble anticancer drugs by more than tenfold and enhances drug targeting specificity to cancer cells, minimizing various side effects that occur during anticancer treatment.

The peptide antibiotic patent for multidrug-resistant super bacteria has a selective bacterial membrane-disrupting mechanism that kills infection-causing super bacteria in the human body within a short time. It is expected to be used as a treatment for various severe infectious diseases such as pneumonia and sepsis, for which there are currently no specific therapies.

The GPCR-targeting peptide metabolic disease treatment patent selectively acts on a specific orphan-GPCR whose ligand has not been identified until now. It includes technical details on the development of new peptide ligands and new metabolic disease platform drugs applicable to the treatment of diabetes, obesity, and other metabolic diseases. Anigen plans to enter nonclinical studies on this patent in the second half of this year.

This content was produced with the assistance of AI translation services.